US FDA accepts NDA for Gadovist injection in magnetic resonance imaging
Bayer Schering Pharma AG, Berlin, Germany, announced that the Food and Drug Administration (FDA) has accepted for filing a New Drug Application to the US for gadobutrol injection, a gadolinium-based contrast agent for magnetic resonance imaging (MRI).
[adsense:336x280:8701650588]